AbbVie stock weekly forecast: Holds gains as buyers stay in control

Traders Union
All News
Stocks
AbbVie slips 0.27% this week

Highlights

Shares of AbbVie closed at $262.47, down $0.45 over 7 days, and remain above both short-term and medium-term supports.
Technical signals show a bullish stance, but overbought readings and low volatility indicate buyers dominate within a narrow range.
Next week, AbbVie is expected to trade between $257.86 and $267.07, with a high probability of price gains and key support at $261.09.

FDA and pipeline updates drive sentiment as bullish flows persist this week

AbbVie's shares drew attention this week after the company received U.S. Food and Drug Administration approval for Juvmo (tavapadon), a once-daily Parkinson’s therapy, as reported by PR Newswire and The Motley Fool. Additional corporate news included new phase 1 data on ABBV-295, AbbVie's diabetes candidate, as presented at EASD 2026, and positive phase 3 results for Rinvoq in non-segmental vitiligo, highlighted by GuruFocus. The company is also set to report third-quarter 2026 results on October 30, 2026, and is investing in AI-driven drug research through a new partnership with Valkai.

Bullish MACD and overbought signals mark week of narrow consolidation

The daily chart points to continued consolidation, with the trend strength flat and momentum character marked by a contained move within a narrow range. MACD remains firmly bullish, while Bull/Bear Power shows an overbought reading, highlighting some upward pressure but also caution as buyers dominate. Notably, volatility over the past week stood at 3.98%. Immediate support is found at $261.09—the 20-day moving average—while resistance aligns with the recent high at $268.59, with the Ichimoku Kijun at $258.39 serving as an additional support reference.

Upside breakout risk rises as next week’s range centers on $261–$268

Next week, AbbVie is expected to trade within a range of $257.86 to $267.07. There is a very high probability of an increase and a very low probability of a decrease. The base case sees the stock consolidating between $261.09 and $268.59, with any sustained move above $268.59 opening a bullish scenario toward the upper end of the range. A close below $261.09 raises the prospect of a move toward the lower boundary near $257.86.

Jainam Mehta, market strategist, notes that shares of AbbVie Inc. held steady near $262 this week, with buyers maintaining control and price action consolidating. Mehta highlights the supportive backdrop of FDA approval for Juvmo and the announcement of positive trial data, which have kept sentiment constructive. On the daily chart, overbought readings and a flat trend suggest upside is likely contained unless $268.59 is cleared, while immediate support remains at $261.09. "I see a tactical opportunity for upside continuation if shares push above resistance, but until then, I would stay patient and let the range between $261.09 and $268.59 play out."

Earlier, analysts noted that AbbVie was likely to extend its period of consolidation with an upward bias, supported by regulatory milestones and advancements in pipeline development. With momentum signals still favoring buyers and volatility elevated, a break above $268.59 would mark a bullish shift to monitor in the coming sessions.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.